Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. (Q39068901)

8 September 2017

Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. (English)

1 reference

8 September 2017

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Charles H Adelmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Kenneth Y. Tsai

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

Vida Chitsazzadeh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

12

Ana M Ciurea

1 reference

4 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

10

Rosamaria Ruggieri

1 reference

4 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

1

Harina Vin

1 reference

4 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

8

Karin Ehrenreiter

1 reference

4 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

Grace Ching

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sandra S Ojeda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

David W Dwyer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Haiching Ma

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Jonathan L Curry

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Madeleine Duvic

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Naifa L Busaidy

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Nizar M Tannir

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

29 October 2013

1 reference

Molecular Cancer Therapeutics

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

221-229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin

4 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Comprehensive analysis of kinase inhibitor selectivity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Sorafenib: a clinical and pharmacologic review

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Keratoacanthomas associated with sorafenib therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Prostate-derived sterile 20-like kinase 2 (PSK2) regulates apoptotic morphology via C-Jun N-terminal kinase and Rho kinase-1

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Mixed lineage kinase ZAK utilizing MKK7 and not MKK4 to activate the c-Jun N-terminal kinase and playing a role in the cell arrest

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Human TAO kinase 1 induces apoptosis in SH-SY5Y cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4366425

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24170769

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-13-0561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24170769%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference